Immutep Limited
IMMPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 15, 2024 | Robert W. Baird | Joel Beatty | $7.00(+560%) | $1.06 | StreetInsider |
| Jun 27, 2024 | Robert W. Baird | Joel Beatty | $6.00(+332%) | $1.39 | TheFly |
| May 17, 2024 | Capital One Financial | Naureen Quibria | $10.00(+585%) | $1.46 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Jun 17, 2026 |
| Citizens | downgrade | Market Outperform →Market Perform | Mar 13, 2026 |
| Baird | downgrade | Outperform →Neutral | Mar 13, 2026 |
| Baird | maintain | Outperform | Nov 15, 2024 |
| Baird | maintain | Outperform | Jun 27, 2024 |
| Baird | maintain | Outperform | Aug 28, 2023 |
| Maxim Group | maintain | Buy | May 18, 2023 |
| Ladenburg Thalmann | maintain | Buy | Aug 3, 2021 |
| Maxim Group | maintain | Buy | May 29, 2018 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-1.45| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 30, 2026 | $-3.11 | $-0.52 | $10.7M | $11.7M |
| Feb 24, 2026 | $-0.22 | $-0.20 | $5.5M | $9.4M |
| Aug 29, 2025 | $-3.72 | $-3.72 | $1.2M | $1.3M |
| Feb 26, 2025 | $-0.10 | $-0.14 | $4.6M | $697.0K |
| Aug 29, 2024 | $-0.12 | $-0.13 | $1.2M | $1.8M |
| Apr 29, 2024 | $-2.41 | $-2.50 | $1.4M | $1.8M |
| Feb 27, 2024 | $-0.12 | $-0.13 | $2.7M | $1.8M |
| Feb 24, 2023 | $-0.15 | $-0.12 | $1.7M | — |
News
SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced positive data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody, from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting of the American College of Rheumatology.
SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), will be presented in poster presentations at two international congresses in November and December 2026.
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $6.08 and traded as low as $3.13. Prima BioMed shares last traded at $3.17, with a volume of 6,783 shares traded. Analyst Ratings Changes Several
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year.
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 760,586 shares, a decrease of 36.4% from the July 30th total of 1,195,547 shares. Based on an average daily trading volume, of 136,177
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima BioMed shares last traded at $0.4035, with a volume of 199,287 shares. Analyst Ratings Changes IMMP has been the subject